• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's Pre-Market Session

    7/27/22 8:08:18 AM ET
    $ADGI
    $AYLA
    $BWV
    $CDTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Specialty Chemicals
    Consumer Discretionary
    Get the next $ADGI alert in real time by email

     

    Gainers

    • Blue Water Vaccines (NASDAQ:BWV) shares rose 60.5% to $3.29 during Wednesday's pre-market session. The market value of their outstanding shares is at $40.4 million.
    • Teva Pharmaceutical Indus (NYSE:TEVA) shares increased by 24.29% to $8.85. The company's market cap stands at $9.8 billion. As per the news, the Q2 earnings report came out yesterday.
    • Cidara Therapeutics (NASDAQ:CDTX) stock rose 22.93% to $0.84. The company's market cap stands at $57.9 million.
    • Chembio Diagnostics (NASDAQ:CEMI) stock rose 13.36% to $0.75. The market value of their outstanding shares is at $22.6 million.
    • Geovax Labs (NASDAQ:GOVX) shares increased by 10.58% to $1.88. The company's market cap stands at $23.5 million.
    • Palisade Bio (NASDAQ:PALI) stock moved upwards by 10.25% to $0.43. The market value of their outstanding shares is at $9.4 million.

    Losers

    • Cassava Sciences (NASDAQ:SAVA) shares declined by 24.4% to $16.42 during Wednesday's pre-market session. The company's market cap stands at $658.1 million.
    • Dermata Therapeutics (NASDAQ:DRMA) shares declined by 10.18% to $0.51. The company's market cap stands at $4.7 million.
    • Revelation Biosciences (NASDAQ:REVBU) stock decreased by 9.73% to $1.3.
    • Adagio Therapeutics (NASDAQ:ADGI) shares fell 9.72% to $3.53. The company's market cap stands at $387.3 million.
    • Ayala Pharmaceuticals (NASDAQ:AYLA) shares declined by 9.47% to $1.53. The market value of their outstanding shares is at $21.5 million.
    • Heart Test Laboratories (NASDAQ:HSCS) stock fell 8.75% to $1.21. The company's market cap stands at $9.9 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ADGI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADGI
    $AYLA
    $BWV
    $CDTX

    CompanyDatePrice TargetRatingAnalyst
    Palisade Bio Inc.
    $PALI
    2/25/2026$5.00Buy
    Stifel
    GeoVax Labs Inc.
    $GOVX
    2/19/2026Buy → Hold
    D. Boral Capital
    Palisade Bio Inc.
    $PALI
    1/9/2026$7.00Buy
    B. Riley Securities
    Palisade Bio Inc.
    $PALI
    12/29/2025$25.00Overweight
    Piper Sandler
    Teva Pharmaceutical Industries Limited
    $TEVA
    12/9/2025$35.00Overweight
    Barclays
    Teva Pharmaceutical Industries Limited
    $TEVA
    12/5/2025$35.00Sector Outperform
    Scotiabank
    Cidara Therapeutics Inc.
    $CDTX
    11/17/2025Overweight → Equal-Weight
    Morgan Stanley
    Cidara Therapeutics Inc.
    $CDTX
    11/17/2025Overweight → Neutral
    Analyst
    More analyst ratings

    $ADGI
    $AYLA
    $BWV
    $CDTX
    SEC Filings

    View All

    SEC Form 10-K filed by Cassava Sciences Inc.

    10-K - FILANA THERAPEUTICS, INC. (0001069530) (Filer)

    3/12/26 4:01:42 PM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cassava Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - FILANA THERAPEUTICS, INC. (0001069530) (Filer)

    3/12/26 8:15:25 AM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cassava Sciences Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - FILANA THERAPEUTICS, INC. (0001069530) (Filer)

    3/10/26 8:15:27 AM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADGI
    $AYLA
    $BWV
    $CDTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cassava Sciences Announces Name Change to Filana Therapeutics, Inc.

    New corporate identity reflects the Company's mission to develop novel medicines to modulate filamin A and address unmet needs in treating TSC-related epilepsy Filana Therapeutics to begin trading under "FLNA" effective March 11, 2026 AUSTIN, Texas, March 10, 2026 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA) today announced the rebranding of the Company, with a name change to Filana Therapeutics, Inc. ("Filana Therapeutics", or the "Company"). The new name and corporate brand reflect the Company's strategic focus on developing novel medicines to modulate the filamin A protein for the treatment of central nervous system (CNS) disorders, such as Tuberous Sclerosis Complex (TSC

    3/10/26 8:00:00 AM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Teva and Blackstone Life Sciences Announce $400 Million Strategic Growth Capital Agreement to Advance duvakitug

    Blackstone Life Sciences will provide $400 million to support development of duvakitug, a human monoclonal antibody targeting TL1ADuvakitug is currently in phase 3 clinical studies for ulcerative colitis (UC) and Crohn's disease (CD)Agreement supports Teva's Pivot to Growth strategy to accelerate its innovative pipeline and drive long-term growth PARSIPPANY, N.J. and CAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and funds managed by Blackstone Life Sciences ("BXLS") today announced a $400 million strategic funding agreement spread across four years to support the continued clinical d

    3/3/26 5:00:00 PM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Palisade Bio Announces Participation in Two Upcoming Investor Conferences

    Carlsbad, CA, March 02, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today announced that management will participate in two upcoming investor conferences taking place during March 2026. Details are as follows: TD Cowen 46th Annual Health Care ConferenceDate/time: March 2, 2026 at 3:10 PM ESTLocation: Boston Mariott Copley Place, Boston, MAFormat: In-person presentation & investor meetingsWebcast link: Register here Investors registered to attend the conference who wish t

    3/2/26 9:00:00 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADGI
    $AYLA
    $BWV
    $CDTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Williams Donald Allen bought $8,356 worth of shares (5,000 units at $1.67), increasing direct ownership by 87% to 10,728 units (SEC Form 4)

    4 - PALISADE BIO, INC. (0001357459) (Issuer)

    1/21/26 4:05:24 PM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Williams Donald Allen bought $9,400 worth of shares (5,000 units at $1.88), increasing direct ownership by 687% to 5,728 units (SEC Form 4)

    4 - PALISADE BIO, INC. (0001357459) (Issuer)

    1/13/26 9:43:07 PM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    President & CEO Stein Jeffrey disposed of $339,040 worth of shares (5,190 units at $65.33), bought $339,040 worth of shares (4,262 units at $79.55), gifted 1,873 shares and received a gift of 937 shares, decreasing direct ownership by 44% to 5,763 units (SEC Form 4)

    4 - Cidara Therapeutics, Inc. (0001610618) (Issuer)

    1/7/26 8:12:25 PM ET
    $CDTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADGI
    $AYLA
    $BWV
    $CDTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    See "Remarks" Sabag Mark converted options into 15,723 units of Ordinary Shares, increasing direct ownership by 6% to 287,042 units (SEC Form 4)

    4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)

    3/9/26 4:23:23 PM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, Chief Financial Officer Kalif Eliyahu Sharon converted options into 19,916 units of Ordinary Shares, increasing direct ownership by 7% to 325,435 units (SEC Form 4)

    4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)

    3/9/26 4:22:06 PM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Accounting Officer Weiss Amir converted options into 3,537 units of Ordinary Shares, increasing direct ownership by 13% to 30,695 units (SEC Form 4)

    4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)

    3/9/26 4:19:34 PM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADGI
    $AYLA
    $BWV
    $CDTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Stifel initiated coverage on Palisade Bio with a new price target

    Stifel initiated coverage of Palisade Bio with a rating of Buy and set a new price target of $5.00

    2/25/26 7:53:12 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    GeoVax Labs downgraded by D. Boral Capital

    D. Boral Capital downgraded GeoVax Labs from Buy to Hold

    2/19/26 8:44:06 AM ET
    $GOVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    B. Riley Securities initiated coverage on Palisade Bio with a new price target

    B. Riley Securities initiated coverage of Palisade Bio with a rating of Buy and set a new price target of $7.00

    1/9/26 9:07:04 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADGI
    $AYLA
    $BWV
    $CDTX
    Leadership Updates

    Live Leadership Updates

    View All

    Palisade Bio Appoints Global IBD Precision Medicine Leader Bram Verstockt, MD, PhD to Clinical Advisory Board

    Appointment strengthens Phase 2 development strategy for PALI-2108 in ulcerative colitis and fibrostenotic Crohn's disease; Phase 2 ulcerative colitis IND submission planned for first half of 2026 Carlsbad, CA, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company advancing next-generation, once-daily oral PDE4 inhibitor prodrugs engineered for targeted delivery to the terminal ileum and colon, today announced the appointment of Bram Verstockt, MD, PhD, to its Clinical Advisory Board (CAB). Dr. Verstockt is an internationally recognized expert in inflammatory bowel disease (IBD) and a leader in precisi

    2/17/26 8:45:00 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Palisade Bio Appoints Leading Global IBD Experts, Laurent Peyrin-Biroulet, MD, PhD and David T. Rubin, MD, to Its Clinical Advisory Board

    Internationally recognized leaders in inflammatory bowel disease bring deep expertise spanning ulcerative colitis, Crohn's disease, and late-stage clinical trial design Appointments strengthen Palisade Bio's clinical strategy as PALI-2108 advances toward Phase 2 development in ulcerative colitis and fibrostenotic Crohn's disease, with a Phase 2 UC IND submission planned for the first half of 2026 Carlsbad, CA, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today an

    1/29/26 8:45:00 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Palisade Bio Strengthens Clinical Leadership Team with Appointment of James Izanec, MD, AGAF as Vice President, Clinical Development

    Veteran gastroenterologist and clinical development leader with deep expertise driving global Phase 2/3 programs across immunology, neurology, and gastrointestinal disease Carlsbad, CA, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company advancing next-generation, once daily, oral PDE4 inhibitor prodrugs for patients with inflammatory and fibrotic diseases, today announced the appointment of James Izanec, MD, AGAF as Vice President, Clinical Development. Dr. Izanec is a physician–scientist with over two decades of clinical and drug development leadership spanning immunology, neuroscience, and gastr

    12/2/25 8:45:00 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADGI
    $AYLA
    $BWV
    $CDTX
    Financials

    Live finance-specific insights

    View All

    Teva Innovative Portfolio and Consistent Execution of Pivot to Growth Strategy Deliver Third Consecutive Year of Growth; Pipeline Positioned to Unlock Significant Value Potential

    Teva delivers 3 consecutive years of growth - 2025 revenues of $17.3 billion, an increase of 4% year-over-year (YoY) in U.S. dollars, or 3% in local currency (LC) terms, compared to 2024. Excluding Japan BV, revenues increased 5% YoY in LC.Key Innovative brands continued to drive growth and provide value for patients, with 2025 revenues surpassing $3 billion, +35% YoY in LC: AUSTEDO® global revenues of $2.26 billion, growing 34% YoY in LC. AJOVY® global revenues of $673 million, up 30% YoY in LC.UZEDY® revenues of $191 million, up 63% YoY in LC; underscoring Teva's commitment to drive new advances in neuroscience: Fastest growing long-acting injectable (LAI)1FDA expanded indicati

    1/28/26 7:00:00 AM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo

    Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 million to support Teva's anti-IL-15 candidate TEV-‘408TEV-‘408 is currently in Phase 1b for treatment of vitiligo and in Phase 2a for celiac diseaseFunding agreement supports Teva's Pivot to Growth strategy to accelerate its innovative pipeline and bring treatments to patients faster PARSIPPANY, N.J., and NEW YORK, Jan. 11, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Royalty Pharma plc (NASDAQ:RPRX), today announced a funding agreement of up to $500 million to accel

    1/11/26 5:00:00 PM ET
    $RPRX
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Teva Releases Q4 2025 Aide Memoire

    TEL AVIV, Israel, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q4 2025 Aide Memoire is available on the "Investors" page on its website. Q4 2025 Aide Memoire Teva has compiled this document with public information that was previously provided by Teva in order to assist investors ahead of fourth quarter 2025 results, which are expected to be released on Wednesday, January 28, 2026 at 7am ET, followed by a conference call at 8am ET. The document is based on Teva's prior results, management's previous commentary about Teva's business outlook and data from select independent sources. About Teva Teva Pharmaceutical Indu

    12/12/25 4:30:00 PM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADGI
    $AYLA
    $BWV
    $CDTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Cidara Therapeutics Inc.

    SC 13G - Cidara Therapeutics, Inc. (0001610618) (Subject)

    12/9/24 5:37:15 PM ET
    $CDTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Cidara Therapeutics Inc.

    SC 13G - Cidara Therapeutics, Inc. (0001610618) (Subject)

    12/4/24 4:15:14 PM ET
    $CDTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Cidara Therapeutics Inc.

    SC 13G - Cidara Therapeutics, Inc. (0001610618) (Subject)

    12/3/24 4:34:49 PM ET
    $CDTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care